Suneeta Reddy, the Managing Director, Apollo Hosp On CNBC-TV18:
\n\nNew Bed Additions Expected To Start Contributing To EBITDA Over The Next Year
\n\nHospitals EBITDA Margin Contracted 60 bps Due To New Bed Commissioning
\n\nOlder Established Beds’ EBITDA Margin Remains At 26%
\n\nOncology Contributes 21% Of Apollo’s Total Revenue
\n\nLimited Impact Expected From The 30% Trade Margin Cap On Oncology Drugs
\n\nStrong Growth In Oncology, Patients Come To Apollo For The Entire Value Chain
\n\nAverage Revenue Per Patient At `1.8 Lakh
\n\nIndraprastha Hospital Continues To Do Well
\n\nAwaiting Court’s Decision On Indraprastha Hospital
\n\nActive Dialogue Taking Place From Hospitals On Possible Caps
\n\nHold On To Previous Guidance Of 18-20% Growth In Hospitals
\n\nNeed To Make Stronger Representation To The Govt And Public On Hospitals
\n\nRajiv Rajgopal, Joint Managing Director and CEO, JSW Dulux On CNBC-TV18:
\n\nAverage Price Increase For The Quarter Was 7%, Exit Was 10%
\n\nTook Another Price Hike In Q3, Cumulative Price Increase At 13%
\n\nSaw Strong Growth In Decorative & Industrial Businesses
\n\nHave Gained 0.3% Market Share In Q3
\n\nAn Additional 2% Anti-Dumping Duty Needs To Be Factored In
\n\nHopeful Of Achieving 12-13% Margin By Year End
\n\nApollo Hospitals MD Suneeta Reddy speaks to CNBC-TV18 post earnigns. Click…
Original source: https://www.cnbctv18.com/entertainment/
